IL285832B2 - Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof - Google Patents

Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof

Info

Publication number
IL285832B2
IL285832B2 IL285832A IL28583221A IL285832B2 IL 285832 B2 IL285832 B2 IL 285832B2 IL 285832 A IL285832 A IL 285832A IL 28583221 A IL28583221 A IL 28583221A IL 285832 B2 IL285832 B2 IL 285832B2
Authority
IL
Israel
Prior art keywords
compound
patient
patients
disease
pulmonary
Prior art date
Application number
IL285832A
Other languages
English (en)
Hebrew (he)
Other versions
IL285832B1 (en
IL285832A (en
Inventor
Melanie Pei-Heng Chin
Colin J Meyer
Original Assignee
Reata Pharmaceuticals Inc
Reata Pharmaceuticals Holdings Llc
Chin Melanie Pei Heng
Colin J Meyer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals Inc, Reata Pharmaceuticals Holdings Llc, Chin Melanie Pei Heng, Colin J Meyer filed Critical Reata Pharmaceuticals Inc
Publication of IL285832A publication Critical patent/IL285832A/en
Publication of IL285832B1 publication Critical patent/IL285832B1/en
Publication of IL285832B2 publication Critical patent/IL285832B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
IL285832A 2013-08-23 2014-08-22 Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof IL285832B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361869527P 2013-08-23 2013-08-23
PCT/US2014/052382 WO2015027206A1 (en) 2013-08-23 2014-08-22 Methods of treating and preventing endothelial dysfunction using bardoxololone methyl or analogs thereof

Publications (3)

Publication Number Publication Date
IL285832A IL285832A (en) 2021-09-30
IL285832B1 IL285832B1 (en) 2023-09-01
IL285832B2 true IL285832B2 (en) 2024-01-01

Family

ID=51794949

Family Applications (3)

Application Number Title Priority Date Filing Date
IL285832A IL285832B2 (en) 2013-08-23 2014-08-22 Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
IL272242A IL272242B (en) 2013-08-23 2016-02-17 Methods for the treatment and prevention of impaired functioning of the endothelium using brodoxolone methyl or its analogs
IL244171A IL244171B (en) 2013-08-23 2016-02-17 Methods for the treatment and prevention of impaired functioning of the endothelium using brodoxolone methyl or its analogs

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL272242A IL272242B (en) 2013-08-23 2016-02-17 Methods for the treatment and prevention of impaired functioning of the endothelium using brodoxolone methyl or its analogs
IL244171A IL244171B (en) 2013-08-23 2016-02-17 Methods for the treatment and prevention of impaired functioning of the endothelium using brodoxolone methyl or its analogs

Country Status (18)

Country Link
US (3) US20150080465A1 (https=)
EP (1) EP3035937B1 (https=)
JP (3) JP6564372B2 (https=)
KR (1) KR102322057B1 (https=)
CN (2) CN105517554B (https=)
AU (2) AU2014308600B2 (https=)
BR (1) BR112016003454B1 (https=)
CA (1) CA2921386A1 (https=)
CL (1) CL2016000405A1 (https=)
EA (1) EA201690456A1 (https=)
IL (3) IL285832B2 (https=)
MX (2) MX380589B (https=)
MY (2) MY198522A (https=)
NZ (4) NZ630951A (https=)
PH (1) PH12016500358B1 (https=)
SG (2) SG10201906113RA (https=)
TW (2) TWI717026B (https=)
WO (1) WO2015027206A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2252283T3 (pl) 2008-01-11 2019-09-30 Reata Pharmaceuticals, Inc. Syntetyczne triterpenoidy i sposoby zastosowania w leczeniu choroby
WO2009129546A1 (en) 2008-04-18 2009-10-22 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17
CA2721665C (en) 2008-04-18 2017-01-24 Reata Pharmaceuticals, Inc. Compounds including an anti-inflammatory pharmacore and methods of use
PL2651902T3 (pl) 2010-12-17 2018-04-30 Reata Pharmaceuticals, Inc. Pirazolilowe i pirymidynylowe tricykliczne enony jako modulatory zapalenia o działaniu przeciwutleniającym
JP6410710B2 (ja) 2012-04-27 2018-10-24 リアタ ファーマシューティカルズ インコーポレイテッド バルドキソロンメチルの２，２−ジフルオロプロピオンアミド誘導体、その多形体および使用方法
WO2013188818A1 (en) 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
WO2014040060A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
TWI649330B (zh) 2013-04-24 2019-02-01 艾伯維有限公司 甲基巴多索龍之２，２－二氟丙醯胺衍生物、其多晶形及其使用方法
BR112016003454B1 (pt) * 2013-08-23 2023-02-14 Reata Pharmaceuticals, Inc. Uso de composto de metil bardoxolona
CN107428698B (zh) 2015-02-12 2021-10-26 里亚塔医药公司 作为抗氧化炎症调节剂的咪唑基三环烯酮
AU2016278040B2 (en) 2015-06-16 2019-07-04 Nanophagix LLC Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
BR112018005861B1 (pt) 2015-09-23 2022-11-22 Reata Pharmaceuticals, Inc Compostos derivados de ácido oleanólico modificado com c4 para a inibição de il-17, composição farmacêutica e usos terapêuticos dos ditos compostos
KR102486434B1 (ko) 2016-11-08 2023-01-09 리아타 파마슈티컬즈 홀딩스, 엘엘씨 바독솔론 메틸 또는 이의 유사체를 사용하는 알포트 증후군의 치료 방법
CN106632574B (zh) * 2016-12-07 2018-05-29 广东天键生物科技有限公司 一种化合物、其制备方法及用途
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
WO2018200692A1 (en) * 2017-04-26 2018-11-01 The Trustees Of The University Of Pennsylvania Methods and systems for virtual and augmented reality training for responding to emergency conditions
IL279348B2 (en) 2018-06-15 2026-01-01 Reata Pharmaceuticals Inc Decahydro-2h-naphth[1,2-d]imidazole compounds for inhibition of IL-17 and ROR-gamma
WO2019246461A1 (en) 2018-06-20 2019-12-26 Reata Pharmaceuticals, Inc. Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
BR112021005919A2 (pt) * 2018-09-28 2021-07-27 Sichuan Haisco Pharmaceutical Co., Ltd. composto, composição farmacêutica e método para tratar uma doença em um mamífero
WO2020080482A1 (ja) * 2018-10-17 2020-04-23 株式会社 資生堂 血液中のシスタチンｃ量に基づく腎機能検査結果の妥当性を検定する方法
TWI861163B (zh) 2019-07-19 2024-11-11 美商瑞塔醫藥有限責任公司 C17經極性取代之雜芳合成三萜類化合物及其使用方法
EP4067367B1 (en) * 2019-11-27 2025-05-28 Lunan Pharmaceutical Group Corporation Oleanane cinnamamide derivative, preparation method therefor, and use thereof
WO2021126884A1 (en) * 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HF-pEF)
WO2021132302A1 (ja) * 2019-12-23 2021-07-01 東レ株式会社 透析移行又は腎死の抑制のための薬剤
WO2021202720A1 (en) * 2020-04-01 2021-10-07 Fronthera U.S. Pharmaceuticals Llc Use of triterpenoid nrf2 inhibitors
JP2023526567A (ja) * 2020-05-09 2023-06-21 リアタ ファーマシューティカルズ ホールディングス リミテッド ライアビリティ カンパニー バルドキソロンメチルまたはそのアナログを用いてｃｏｖｉｄ－１９を処置する方法
CN111704647B (zh) * 2020-06-15 2021-10-22 中国人民解放军海军军医大学 一类三萜类衍生物及其作为程序性细胞坏死抑制剂的用途
US20240293351A1 (en) 2020-12-11 2024-09-05 Reata Pharmaceuticals Holdings, LLC Methods of administering synthetic triterpenoids
US12064409B2 (en) 2021-06-22 2024-08-20 Vanderbilt University Action of L-citrulline to prevent or treat endothelial dysfunction
CN114097807B (zh) * 2021-11-25 2023-05-05 兰州大学 巴多索隆类化合物在抗农业病原真菌中的用途
CN116509874A (zh) * 2023-02-01 2023-08-01 潍坊医学院附属医院 甲基巴多索隆在制备改善病毒性心肌炎或病毒性心肌损伤的药物中的用途
CN117964678A (zh) * 2024-01-29 2024-05-03 烟台大学 C17位杂芳族羰基修饰的齐墩果烷三萜衍生物及其制备方法和用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
AU1772992A (en) 1991-04-10 1992-11-17 Biosite Diagnostics Incorporated Crosstalk inhibitors and their uses
JP3290988B2 (ja) 1991-04-11 2002-06-10 バイオサイト・ダイアグノスティックス・インコーポレイテッド 多重リガンドを同時検出する新規接合体及び検定法
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
GB9212302D0 (en) 1992-06-10 1992-07-22 Applied Research Systems Method for improving measurement precision in evanescent wave optical biosensor assays
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6025395A (en) 1994-04-15 2000-02-15 Duke University Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
DK1465615T3 (da) 2002-01-15 2012-11-12 Dartmouth College Tricykliske bisenonderivater og fremgangsmåder til anvendelse heraf
PE20040468A1 (es) * 2002-05-17 2004-09-14 Novartis Ag Combinacion de compuestos organicos
CA2412856A1 (en) * 2002-11-27 2004-05-27 Frederic Bodin Pharmaceutical composition for the treatment of pulmonary arterial hypertension
US20050239867A1 (en) * 2004-04-23 2005-10-27 Zeldis Jerome B Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension
US7714012B2 (en) 2006-11-17 2010-05-11 Trustees Of Dartmouth University Synthesis and biological activities of new tricyclic-bis-enones (TBEs)
JP5570415B2 (ja) 2007-05-08 2014-08-13 アボット・ラボラトリーズ 他のペプチド型に対する交差反応性の低いヒトｂ型ナトリウム利尿ペプチドアッセイ
US8088824B2 (en) * 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
PL2252283T3 (pl) * 2008-01-11 2019-09-30 Reata Pharmaceuticals, Inc. Syntetyczne triterpenoidy i sposoby zastosowania w leczeniu choroby
WO2009129546A1 (en) 2008-04-18 2009-10-22 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17
WO2009146216A2 (en) * 2008-04-18 2009-12-03 Reata Pharmaceuticals. Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
CN102164941B (zh) 2008-04-18 2015-05-27 里亚塔医药公司 抗氧化剂炎症调节剂:具有饱和c环的齐墩果酸衍生物
RS55631B1 (sr) 2008-04-18 2017-06-30 Reata Pharmaceuticals Inc Antioksidansni modulatori upale: c-17 homologisani derivati oleanolinske kiseline
CA2721665C (en) 2008-04-18 2017-01-24 Reata Pharmaceuticals, Inc. Compounds including an anti-inflammatory pharmacore and methods of use
SMT201900432T1 (it) 2009-02-13 2019-09-09 Reata Pharmaceuticals Inc Composizioni di dosaggio orali, a rilascio ritardato contenenti cddo-me amorfo
MX357596B (es) * 2010-04-12 2018-07-16 Reata Pharmaceuticals Inc Método para tratar obesidad utilizando moduladores de inflamación con antioxidantes.
BR112016003454B1 (pt) * 2013-08-23 2023-02-14 Reata Pharmaceuticals, Inc. Uso de composto de metil bardoxolona

Also Published As

Publication number Publication date
IL272242A (en) 2020-02-27
JP6701407B2 (ja) 2020-05-27
PH12016500358B1 (en) 2023-08-16
BR112016003454A2 (pt) 2017-08-01
IL285832B1 (en) 2023-09-01
NZ744036A (en) 2020-09-25
IL272242B (en) 2021-09-30
EA201690456A1 (ru) 2016-06-30
AU2014308600B2 (en) 2020-03-05
PH12016500358A1 (en) 2016-05-16
CA2921386A1 (en) 2015-02-26
MX380589B (es) 2025-03-12
WO2015027206A1 (en) 2015-02-26
WO2015027206A8 (en) 2015-06-11
KR102322057B1 (ko) 2021-11-05
MX2021002897A (es) 2021-06-08
TW202026003A (zh) 2020-07-16
NZ756256A (en) 2021-07-30
BR112016003454B1 (pt) 2023-02-14
TWI717026B (zh) 2021-01-21
AU2020203510B2 (en) 2023-05-11
EP3035937B1 (en) 2025-12-31
MY198522A (en) 2023-09-04
MY205497A (en) 2024-10-23
JP6526306B2 (ja) 2019-06-05
JP2019131599A (ja) 2019-08-08
IL244171B (en) 2020-02-27
CN112870202A (zh) 2021-06-01
NZ630951A (en) 2018-09-28
AU2020203510A1 (en) 2020-06-18
SG10201906113RA (en) 2019-08-27
JP2016528300A (ja) 2016-09-15
US20240115542A1 (en) 2024-04-11
CN105517554B (zh) 2021-01-15
CL2016000405A1 (es) 2017-02-24
AU2014308600A1 (en) 2016-03-03
CN105517554A (zh) 2016-04-20
JP6564372B2 (ja) 2019-08-21
KR20160061994A (ko) 2016-06-01
JP2019048873A (ja) 2019-03-28
SG11201601202WA (en) 2016-03-30
TWI716341B (zh) 2021-01-21
EP3035937A1 (en) 2016-06-29
US20190091194A1 (en) 2019-03-28
NZ774222A (en) 2023-01-27
TW201542211A (zh) 2015-11-16
US20150080465A1 (en) 2015-03-19
HK1223015A1 (zh) 2017-07-21
MX2016002375A (es) 2016-12-20
IL244171A0 (en) 2016-04-21
IL285832A (en) 2021-09-30

Similar Documents

Publication Publication Date Title
AU2020203510B2 (en) Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
AU2024200693B2 (en) Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof
HK1223015B (zh) 使用甲基巴多索隆或其类似物治疗和预防内皮功能障碍的方法
HK40052300A (en) Methods of treating and preventing a renal disease using bardoxolone methyl or analogs thereof
EA042085B1 (ru) Способ лечения и предотвращения заболевания почек
HK40011743A (en) Methods of treating alport syndrome using bardoxolone methyl or analogs thereof
HK40011743B (en) Methods of treating alport syndrome using bardoxolone methyl or analogs thereof